Should I buy or sell Clene stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares. View CLNN analyst ratings or view top-rated stocks .

What is Clene's stock price target for 2024?

4 equities research analysts have issued 1 year price targets for Clene's stock. Their CLNN share price targets range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 1,870.3% from the stock's current price. View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts .

How have CLNN shares performed in 2024?

Clene's stock was trading at $0.2966 at the start of the year. Since then, CLNN stock has increased by 11.2% and is now trading at $0.3299. View the best growth stocks for 2024 here .

Are investors shorting Clene?

Clene saw a drop in short interest in March. As of March 31st, there was short interest totaling 162,900 shares, a drop of 37.9% from the March 15th total of 262,500 shares. Based on an average trading volume of 743,600 shares, the short-interest ratio is currently 0.2 days. View Clene's Short Interest .

When is Clene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our CLNN earnings forecast .

How were Clene's earnings last quarter?

Clene Inc. (NASDAQ:CLNN) released its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm earned $0.17 million during the quarter, compared to analyst estimates of $0.14 million. Clene had a negative trailing twelve-month return on equity of 253.48% and a negative net margin of 7,569.42%.

How do I buy shares of Clene?

Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CLNN

Clene (CLNN) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CLNN Stock Alerts

$0.33

-0.01 (-2.94%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.31
▼
$0.34
50-Day Range: $0.31
▼
$0.50
52-Week Range: $0.25
▼
$1.09

Volume: 1.34 million shs
Average Volume: 991,391 shs
Market Capitalization: $42.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.50

Get Clene alerts:

Clene MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,870.3% Upside
$6.50 Price Target
Short Interest: Healthy
0.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.05
Based on 6 Articles This Week
Insider Trading: Selling Shares
$8,775 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.33) to ($0.32) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.93 out of 5 stars

Medical Sector

366th out of 918 stocks

Biotechnology Industry

9th out of 41 stocks

3.5

Analyst's Opinion

Consensus Rating
Clene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Clene has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.13% of the outstanding shares of Clene have been sold short.
Short Interest Ratio / Days to Cover
Clene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Clene has recently decreased by 37.94%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Clene does not currently pay a dividend.
Dividend Growth
Clene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLNN.

1.7

News and Social Media Coverage

News Sentiment
Clene has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Clene this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Clene to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,775.00 in company stock.
Percentage Held by Insiders
26.60% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 23.28% of the stock of Clene is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Clene are expected to grow in the coming year, from ($0.33) to ($0.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Clene is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clene is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Clene has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Clene Stock (NASDAQ:CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

CLNN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLNN Stock News Headlines

April 18, 2024 | americanbankingnews.com

Clene's (CLNN) Buy Rating Reaffirmed at HC Wainwright

April 17, 2024 | benzinga.com

The Analyst Verdict: Clene In The Eyes Of 5 Experts

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 16, 2024 | msn.com

Clene stock rallies 52% post-market on MS drug data

April 16, 2024 | globenewswire.com

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

March 27, 2024 | theglobeandmail.com

Clene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

March 26, 2024 | investorplace.com

3 Penny Stocks That Could Be Multibaggers in the Making: March Edition

March 19, 2024 | finance.yahoo.com

IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 17, 2024 | morningstar.com

Clene Inc Ordinary Shares

March 16, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market Dynamics

March 15, 2024 | globenewswire.com

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

March 13, 2024 | finanznachrichten.de

Clene Inc.: Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

March 13, 2024 | markets.businessinsider.com

Breaking Down Clene: 4 Analysts Share Their Views

March 13, 2024 | benzinga.com

Clene: Q4 Earnings Insights

March 13, 2024 | globenewswire.com

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

March 7, 2024 | finance.yahoo.com

Clene to Present at the 36th Annual ROTH Conference

February 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Clene’s CNM-Au8 on Promising Long-Term Clinical Outcomes

February 29, 2024 | globenewswire.com

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

February 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Clene Amidst Strong Clinical Data and Financial Stability

February 22, 2024 | markets.businessinsider.com

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

February 17, 2024 | finance.yahoo.com

CLNN Mar 2024 1.000 put

February 17, 2024 | finance.yahoo.com

CLNN Mar 2024 3.000 call

February 8, 2024 | theglobeandmail.com

Clene (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview

February 6, 2024 | finance.yahoo.com

Ibogaine By David Dardashti Offers Free Online Support for Post-Treatment Care

February 6, 2024 | theglobeandmail.com

Clene (NASDAQ: CLNN) Reports Statistically Significant Long-Term Improvements for VISIONARY-MS Participants

January 24, 2024 | finance.yahoo.com

Clene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatment

See More Headlines

Receive CLNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CLNN
CUSIP: N/A
CIK: 1822791
Web: clene.com
Phone: 801-676-9695
Fax: N/A
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.50
High Stock Price Target: $10.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +1,814.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,500,000.00
Net Margins: -7,569.42%
Pretax Margin: -7,569.42%
Return on Equity: -253.48%
Return on Assets: -62.88%

Debt

Debt-to-Equity Ratio: 0.53
Current Ratio: 1.53
Quick Ratio: 1.53

Sales & Book Value

Annual Sales: $650,000.00
Price / Sales: 67.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.10 per share
Price / Book: 3.40

Miscellaneous

Outstanding Shares: 128,430,000
Free Float: 94,268,000
Market Cap: $43.61 million
Optionable: Optionable
Beta: 0.50

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Robert Etherington MBA (Age 57)
CEO, President & Director
Comp: $590.98k
Mr. Morgan R. Brown CPA (Age 56)
M.B.A., Chief Financial Officer
Comp: $374.05k
Mr. Mark G. Mortenson ESQ. (Age 66)
Chief Science Officer
Comp: $482.98k
Mr. Jerry Miraglia J.D.
General Counsel & Corporate Secretary
Mr. Michael T. Hotchkin
Chief Development Officer
Ms. Mary Anne Mcneil
Head of Human Resources
Dr. Benjamin M. Greenberg M.D.
M.H.S., Head of Medical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLNN Stock Analysis - Frequently Asked Questions

Should I buy or sell Clene stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clene in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLNN shares.
View CLNN analyst ratings or view top-rated stocks.
What is Clene's stock price target for 2024?: 4 equities research analysts have issued 1 year price targets for Clene's stock. Their CLNN share price targets range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $6.50 in the next twelve months. This suggests a possible upside of 1,870.3% from the stock's current price.
View analysts price targets for CLNN or view top-rated stocks among Wall Street analysts.
How have CLNN shares performed in 2024?: Clene's stock was trading at $0.2966 at the start of the year. Since then, CLNN stock has increased by 11.2% and is now trading at $0.3299.
View the best growth stocks for 2024 here.
Are investors shorting Clene?: Clene saw a drop in short interest in March. As of March 31st, there was short interest totaling 162,900 shares, a drop of 37.9% from the March 15th total of 262,500 shares. Based on an average trading volume of 743,600 shares, the short-interest ratio is currently 0.2 days.
View Clene's Short Interest.

When is Clene's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our CLNN earnings forecast.
How were Clene's earnings last quarter?: Clene Inc. (NASDAQ:CLNN) released its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm earned $0.17 million during the quarter, compared to analyst estimates of $0.14 million. Clene had a negative trailing twelve-month return on equity of 253.48% and a negative net margin of 7,569.42%.
How do I buy shares of Clene?: Shares of CLNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLNN) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial